Home > Journals > Minerva Pediatrica > Past Issues > Articles online first > Minerva Pediatrica 2017 Jul 27

CURRENT ISSUE
 

ARTICLE TOOLS

Publication history
Reprints
Cite this article as

MINERVA PEDIATRICA

A Journal on Pediatrics, Neonatology, Adolescent Medicine,
Child and Adolescent Psychiatry


Indexed/Abstracted in: CAB, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 0,764


eTOC

 

Minerva Pediatrica 2017 Jul 27

DOI: 10.23736/S0026-4946.17.04874-5

Copyright © 2017 EDIZIONI MINERVA MEDICA

language: English

Pediatric Mesenchymal Stromal Cells (MSC) therapy: an update

Qi AN, Conghai FAN , Shumei XU

Department of Internal Medicine, Xuzhou Children’s Hospital, Jiangsu, P.R. China


PDF  


The mesenchymal have heterogeneous composition and till date no single, definitive marker for their identification is available. Further, this cell population is identified by their adherence to plastic, spindle-like morphology and their tri-lineage plasticity. They also have ability to differentiate into bone, cartilage and fat. Moreover, MSC as “Multipotent stromal cells” (MSC) is a preferred choice over “Mesenchymal stem cells” as the later definition includes many cell populations, several of which do not fulfill the self-renewal and multi-lineage potential of true stem cells. So, the present review article is focused to enlighten recent views of MSC therapy in the filed of pediatrics.


KEY WORDS: Pediatrics - MSC therapy - Mesnchymal

top of page

Publication History

Article first published online: July 27, 2017
Manuscript accepted: May 26, 2017
Manuscript revised: May 4, 2017
Manuscript received: December 6, 2016

Cite this article as

Pediatric Mesenchymal Stromal Cells (MSC) therapy: an update. Minerva Pediatr 2017 Jul 27. DOI: 10.23736/S0026-4946.17.04874-5

Corresponding author e-mail

fanconghai020@163.com